AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04058314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gemini IV
Description: Eyes randomized to receive the Gemini IV device will receive the study device in conjunction with an approved monofocal or toric IOL post cataract extraction
Study NCT04058314 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Eye
Description: Control eyes will receive an approved monofocal or toric IOL post cataract extraction
Study NCT04055480 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-loop using standard rapid-acting insulin
Description: Closed-loop using standard rapid-acting insulin
Study NCT04055480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop using faster insulin aspart
Description: Closed-loop using faster insulin aspart
Study NCT00547261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSR97225
Description: every 3 weeks
Study NCT03783702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 Mg (milligram) Oral Tablet
Description: Patients in the experimental group will receive ibuprofen 600mg as the second-line analgesic.
Study NCT03783702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 650 MG (milligram) Oral Tablet
Description: All patients will receive acetaminophen as the first-line analgesic.
Study NCT03783702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 MG (milligram) Oral Tablet
Description: All patients will receive acetaminophen as the first-line analgesic.
Study NCT03239028 — intervention group
Intervention type: BEHAVIORAL
Intervention: Observational
Study NCT02399475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L
Study NCT02399475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liothyronine
Description: Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L
Study NCT02399475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thyrotropin-Releasing Hormone
Description: 200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).
Study NCT02088216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: 600mg po twice a day for 12 months
Study NCT02088216 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: On-demand treatment
Description: receive as-needed therapy
Study NCT00843622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-nitrosamine smokefree tobacco product for oral use
Description: Smokeless tobacco in paper sachets containing 1.0 or 0.5 g of the product. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke >15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
Study NCT00843622 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-tobacco, non-nicotine placebo product
Description: Placebo product in paper sachets containing 1.0 or 0.5 g. Product made of cocoa bean fibers and oat fibers. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke >15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
Study NCT04788199 — intervention group
Intervention type: OTHER
Intervention: Closure of mesenteric defects using glue
Description: Cyano-acrylate glue is a glue known to be used in surgery as tissue adhesive.
Study NCT01283191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Incentives
Description: Vouchers for complying with target behavior of treadmill walking
Study NCT01283191 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Education Control
Description: Education class
Study NCT00606697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GR205171
Description: 10 milligrams (mg)
Study NCT00606697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW597599
Description: 15 mg
Study NCT01383044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVL + carvedilol
Description: EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
Study NCT01383044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carvedilol
Description: carvedilol 6.25mg-12.5 mg per day
Study NCT00594152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIIIT
Description: The intravenous infusion group received three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to subcutaneous insulin.
Study NCT03601338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bemiparin
Description: second generation low molecular weight Heparin
Study NCT03601338 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: multivitamins and routine antenatal follow up
Description: multivitamins and routine antenatal follow up
Study NCT02788916 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Study NCT02025738 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MAGNET APPLICATION
Study NCT00804973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sumatriptan
Description: 6 milligrams (mg) injection (0.5 milliliter \[mL\] of 12 mg/mL solution), once
Study NCT00804973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: 4 capsules, once
Study NCT00804973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo capsule
Description: 4 capsules, once
Study NCT03624868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: See above description
Study NCT03624868 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wellness Education
Description: See above description
Study NCT04097041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanomastoidectomy
Description: Patient undergoes tympanomastoidectomy (approx 2 hour operation on ear and mastoid) where a local soft tissue flap is transferred to cover the sigmoid sinus, a cartilage and perichondrial graft is taken from the tragus to cover the jugular bulb).
Study NCT04097041 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Surgery
Description: Screening performed at outpatient clinic after consultation for management of venous pulsatile tinnitus. Consent and formal recruitment into study performed at preoperative visit or at audiological visit.~The masking device is a hearing aid that provides sound that is aimed to negate the internal sound from the pulsatile tinnitus. Almost all hearing aid can be converted to a masking device for tinnitus. It is externally worn on the ear and provides sound at a desired volume. The benefits of wearing the masking device are that it may reduce the volume of the pulsatile tinnitus. As it is worn on the external ear and is not invasive there are minimal risks but potential risks could include irritation of the external ear and discomfort from wearing.
Study NCT00724958 — intervention group
Intervention type: BIOLOGICAL
Intervention: Infliximab
Description: Not specified in the protocol.
Study NCT03572582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab therapy combined with standard TACE treatment
Study NCT03572582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE is performed by using drug eluting beads
Study NCT01301937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate
Description: Meglumine antimoniate (Aventis, São Paulo, Brazil) is stored and ministered under actual conditions employed by the health services in Brazil. Each patient will be included in one of two treatment groups with meglumine antimoniate IM:~1. High continuous dose: 20 mg/kg/day for 30 continuous days.~2. Low continuous dose 5 mg/kg/day for up to 120 continuous days.~There will be no cross-over between the groups for the purpose of this study. The data from those patients who require permanent discontinuation of a scheme will be assessed in the group that were randomized, ie, by intention to treat~Arms: High continuous dose, Low continuous dose
Study NCT02751424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3342830
Description: A pyrogen free lyophilized formulation, white to yellowish brown powder containing 1000 mg of GSK3342830A (as free base) per vial. The reconstituted solution looks like a clear, colorless to yellow or brownish yellow liquid, free from visible particulate matter will be administered as IV infusion over 1 hour.
Study NCT02751424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A clear and colorless solution containing 0.9% sodium chloride. It will administered as IV infusion over 1 hour.
Study NCT03174158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mailed nicotine replacement therapy
Description: Daily smokers will be offered patches and lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette). Non-daily smokers will be offered a 2 week supply of 2 mg lozenges. Smokers not ready to quit will be offered one box of lozenges dosed according to time to first cigarette to use in a practice quit attempt.
Study NCT03174158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging
Description: 12 week text messaging program tailored to readiness to quit and quit date. Program includes content encouraging NRT use. Content is personalized with user's name and Massachusetts General Hospital resources.
Study NCT03174158 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice
Description: Brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training
Study NCT03174158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief advice
Description: Brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training
Study NCT02342509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Group A: Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
Study NCT02342509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Group B: Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
Study NCT02342509 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: Group C: Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
Study NCT01720953 — intervention group
Intervention type: OTHER
Intervention: Mentalization Based Therapy
Description: Fifty female patients diagnosed with BPD will undergo a year of intensive Mentalization Based Therapy that is designed to target domains of BPD pathology. The patients will be assessed at baseline and every 6 months over the treatment period.
Study NCT02025738 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REPROGRAMING
Study NCT01519947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Participants received 50-250 mcg SC according to local label
Study NCT01519947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methoxy polyethylene glycol-epoetin beta
Description: Participants received 50-250 mcg SC according to local label
Study NCT02921282 — intervention group
Intervention type: GENETIC
Intervention: Genotype dopamine
Description: Laboratory investigations of nicotine reinforcement
Study NCT01800955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: resistive capacitive diathermy treatment (resistive capacitive diathermy, Hcr 902, Unibell)
Description: The resistive capacitive diathermy is a medical device supplying low (448 KHz) radiofrequencies with maximum output power of 200 W. It is used to reduce pain and inflammation and allowing healing processes. diathermy treatment is administered for a thirty minutes session, three times per week for a total of ten sessions.
Study NCT01800955 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham placebo resistive capacitive diathermy treatment
Description: The sham treatment is administered with the diathermy device set on on but not active (not supplying energy) and the treatment session has the same modalities, frequency and duration of experimental diathermy group
Study NCT01029600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic capsular release
Description: Surgical division of thickened capsule in the shoulder
Study NCT02921282 — intervention group
Intervention type: GENETIC
Intervention: Genotype cannabinoids
Description: Laboratory investigations of nicotine reinforcement
Study NCT01029600 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distention with steroid
Description: Intraarticular distention with steroid, saline, contrast and local anaesthetic
Study NCT02303574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7986, oral solution, 1 to 50 mg/mL
Description: Starting dose in single ascending dose part: 5 mg
Study NCT02303574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, oral solution
Description: Matching placebo
Study NCT01582243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50 mg plus metformin 500 mg as Single Pill combination (SPC)
Study NCT03695289 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iOTA SMI
Description: Participants randomized to the iOTA SMI arm will undergo an assessment of individual behavior risks, will participate in collaborative goal-setting with a health coach, and will use an interactive text system that will provide ongoing support and self-monitoring of behavior change goals.
Study NCT03695289 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control
Description: Participants randomized to the Health Education Control arm will receive monthly counseling on energy balance, physical activity and nutrition.
Study NCT04019821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glulisine
Description: A type of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
Study NCT02025738 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NO ACTION
Study NCT03974646 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led self-management Program
Description: Group-based sessions will be scheduled at week two, week four and week six. Participant will be given a printed booklet Participants will receive three individual follow-up phone calls of 20-30 minutes each at week three, week five and week seven.
Study NCT03827577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical removal of primary and/or of all oligometastases
Description: Standard lobectomy or segmentectomy if tumor resectable without pneumonectomy (prefer lobectomy if cardiorespiratory function is not or only moderately compromised, prefer segmentectomy if primary tumor less than 2 cm or cardiorespiratory function is more than moderately compromised but still permissive) Mediastinal lymph node dissection (at least 8 lymphnodes from at least 3 stations including station 7).
Study NCT03827577 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Non-surgical LAT
Description: Non-surgical LAT may be carried out either by SABR or SBRT or RFA according to site of metastasis, local expertise and availability of resources.
Study NCT03827577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy
Description: platinum-based doublet according to local protocols or targeted agents according to EGFR/ALK/ROS-1 mutational status or immunotherapy agents according to PDL1 expression.
Study NCT03827577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medical therapy
Description: platinum-based doublet according to local protocols or targeted agents according to EGFR/ALK/ROS-1 mutational status or immunotherapy agents according to PDL1 expression.
Study NCT01467856 — intervention group
Intervention type: PROCEDURE
Intervention: PAP Device Procedure
Description: Following titration, subjects will be issued a PAP machine programmed at this optimum pressure and instructed to use the device nightly for the ensuing three months. Compliance checks will be conducted at months 1 and 3 by having the subjects present the PAP Smartcard for download and interpretation.~Daily compliance will be reported as the total number of hours of PAP use per 24 hour period. Patients who use PAP > 4 hours/ night for more than 50% of the nights at one month and 3 month follow-up will be classified as 'compliant' with PAP. Non-compliance will be addressed by a clinical problem-solving approach normally utilized by sleep laboratory personnel in the UM PAP clinic.
Study NCT04089085 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: STRONGer Together
Description: STRONGer (Successes/Strengths, Triggers, Remember your medications, Ongoing communication, Never give up!, Gratitude) Together is an asthma educational and cognitive behavioral skills intervention for children between 8 - 12 years of age. The intervention is implemented in small groups in 30-minute sessions.
Study NCT02496754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH-a
Description: In experimental group, patients use long term GnRH-a; Patients' serum or follicle fluid will be collected if needed.
Study NCT03005834 — intervention group
Intervention type: OTHER
Intervention: incidence of cancers
Description: With a continuous surveillance system to track all subsequent incidents of CVD and/or non-CVD via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified.
Study NCT02507063 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasound
Description: Ocular ultrasound to look at the optic nerve sheath diameter in patients with an intracranial monitoring device or with a ventriculoperitoneal shunt malfunction requiring revision
Study NCT05021276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib and basiliximab are both second-line treatment for grade 3-4 steroid-resistant acute graft-versus-host disease.
Study NCT00521508 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: gene transcription and cytometry
Description: samply of 30 ml of blood
Study NCT01477216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELSA 1-9
Description: Measuring GI and II values for Finnish foods
Study NCT00664196 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene Modified T Cells
Description: One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
Study NCT02664415 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: 40 mg/kg; administered IV
Study NCT02664415 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VRC01
Description: Sodium Chloride for Injection 0.9%, USP; administered IV
Study NCT03749707 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV analysis
Description: HPV analysis of SLNs
Study NCT01969760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Families DC Program
Description: A tailored family-based intervention for health promotion goal setting, substance use prevention, and promotion of physical activity
Study NCT04019821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glulisine
Description: A type of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.
Study NCT04019821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart
Description: A type of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
Study NCT04019821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Aspart
Description: A type of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.
Study NCT04019821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: A type of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.
Study NCT04484090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vertica RF device
Description: The treatment provided by the Vertica device is indicated for improving the erectile function in men with erectile dysfunction
Study NCT03611387 — intervention group
Intervention type: DEVICE
Intervention: CASIA 2 OCT
Description: Using CASIA 2 OCT to assess the anterior chamber angle of the eye in the glaucomatous patients withconventional imaging methods
Study NCT02509286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2600 mg/m² (24 hours), d1 every two weeks;
Study NCT02509286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200 mg/m² in 250 ml NaCl 0.9%, d1 every two weeks;
Study NCT02509286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m² in 500 ml G5% over 2h, d1 every two weeks;